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Terminalia  arjuna  is a tree having  an  extensive  medicinal  potential  in  cardiovascular  dis-
orders.  Triterpenoids  are  mainly  responsible  for  cardiovascular  properties.  Alcoholic  and
aqueous  bark extracts  of  T. arjuna,  arjunic  acid,  arjunetin  and  arjungenin  were  evaluated
for their  potential  to inhibit  CYP3A4,  CYP2D6  and  CYP2C9  enzymes  in  human  liver  micro-
somes.  We  have  demonstrated  that  alcoholic  and  aqueous  bark  extract  of T.  arjuna  showed
potent  inhibition  of  all three  enzymes  in  human  liver  microsomes  with  IC50 values  less  than
50  g/mL.  Arjunic  acid,  arjunetin  and arjungenin  did  not  show  signiﬁcant  inhibition  of CYP
enzymes  in human  liver  microsomes.  Enzyme  kinetics  studies  suggested  that  the  extractsTerminalia arjuna
Human liver microsomes
CYP inhibition
Herb–drug interactions
Toxicity
of  arjuna  showed  reversible  non-competitive  inhibition  of  all the three  enzymes  in human
liver  microsomes.  Our  ﬁndings  suggest  strongly  that  arjuna  extracts  signiﬁcantly  inhibit
the activity  of CYP3A4,  CYP2D6  and  CYP2C9  enzymes,  which  is  likely  to cause  clinically
signiﬁcant  drug–drug  interactions  mediated  via inhibition  of  the  major  CYP  isozymes.
© 2015  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
1. IntroductionAbout 70% of the world population currently uses
medicinal herbs as complementary or alternative
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medicine. Herb–drug interactions (HDI) are one of
the most important clinical concerns in the concomitant
consumption of herbs and prescription drugs. The neces-
sity of polypharmacy in the management of most diseases
further increases the risk of HDI in patients [8].
In the Indian system of medicine, Ayurveda, the bark
of the tree Terminalia arjuna (T. arjuna), which is popularly
known as ‘Arjuna’ in many Indian languages, is used as a
cardioprotective agent [12]. As a whole T. arjuna,  i.e., stem
bark, fruit, leaves and roots is associated with therapeu-
tic properties. Particularly, T. arjuna bark extract has been
reported to play a signiﬁcant role as a cardiac stimulant
for its beneﬁcial effects in angina, i.e., “hritshool”, and is
stipulated in the treatment of hypercholesterolemia, heart
failure and atherosclerosis [4].
is is an open access article under the CC BY-NC-ND license
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(Fig. 1. Structures of triterpenoids studied.
It is believed that the saponin glycosides in T. arjuna
ay be responsible for its inotropic effects, while the
avonoids/phenolics may  provide antioxidant activity as
ell as vascular strengthening activity, thereby conﬁrming
he multiple activities of this medicinal plant for its cardio-
rotective role [5].
It is well documented that the ability of intestinal and
epatic cytochrome P450 to metabolize numerous struc-
urally unrelated compounds, apart from being responsible
or the poor oral bioavailability of numerous drugs, is
esponsible for the large number of documented drug–drug
nd drug–food interactions [8]. A notable example of this
s the inhibition of CYP3A by grapefruit juice, which can
esult in elevations of systemic exposure to CYP3A-cleared
ompounds [15].
Three P450 gene families (i.e., CYPl, CYP2, and CYP3)
f the 27 families identiﬁed are currently thought to be
esponsible for the majority of hepatic drug metabolism.
ix principle enzymes (CYP1A2, CYP2C8, CYP2C9, CYP2C19,
YP2D6 and CYP3A4) appear to be the most com-
only responsible for the metabolism of most drugs
nd the associated drug–drug interactions in humans
9].
Despite the understanding of the immense potential
f T. arjuna as a cardioprotective agent, there is a lack of
nformation on its interaction with cytochrome enzymes.
reviously, we have reported the CYP1A interaction of
rjuna extracts, arjunic acid and arjungenin in rat and
uman liver microsomes [24].
Here we report the in vitro inhibition potential of alco-olic and aqueous bark extracts of arjuna, arjunic acid,
rjunetic and arjungenin to inhibit CYP3A4, CYP2D6 and
YP2C9 enzyme activities in human liver microsomes
HLM).nic acid; (b) arjunetin; and (c) arjungenin.
2. Materials and methods
2.1. Chemical and reagents
Testosterone and 6-hydroxy testosterone were gift
samples from Avik Pharma, Vapi, Gujarat and Piramal
Life Sciences Ltd., Mumbai, respectively. Dextrometor-
phan and dextrorphan were gift samples from Aarti Drugs
Pvt. Ltd. and Advinus Therapeutics Pvt. Ltd., respectively.
4′-Hydroxy diclofenac was a gift sample from Advinus
Therapeutics Pvt. Ltd. Diclofenac, caffeine and serotonin
were purchased from Sigma–Aldrich Ltd. Nicotinamide
adenine dinucleotide phosphate reduced tetrasodium salt
(NADPH) was  purchased from Sisco Research Laborato-
ries (SRL) Pvt. Ltd. Arjunic acid (Fig. 1; 95.1% purity),
arjunetin (Fig. 1; 98.2% purity) and arjungenin (Fig. 1; 96.2%
purity) were purchased from Natural Remedies, Bangalore,
India. Pooled human liver microsomes (HLM) of 20 indi-
vidual male donors (Batch No. 0710112) were purchased
from Krishgen Biosystems. All solvents were of high per-
formance liquid chromatography (HPLC) grade and were
purchased from Thermo Fischer Scientiﬁc India Pvt. Ltd.
Double distilled water ﬁltered through 0.45  ﬁlter was
used for the study.
2.2. Preparation of alcoholic and aqueous bark extract of
T. arjuna
Fresh bark of T. arjuna specimens sourced from differ-
ent trees was  purchased from Zandu Foundation, Gujarat,
India. Each of the specimens were identiﬁed visually for
typical arjuna bark characteristics by Dr. Naik, Senior
Research Scientist, Piramal Life Sciences Ltd. and were
further authenticated by Agharkar Research Institute,
ology Re808 A. Varghese et al. / Toxic
Pune with the voucher specimen (S/B 104) deposited for
future reference. The fresh bark was dried in vacuum
oven at temperature not exceeding 55 ◦C. Initially, 500 g
(approximately) of dried powdered bark was defatted with
2 L of petroleum ether for 2 days with intermittent shaking.
Following which the defatted sample was subjected to
cold maceration using 2 L absolute ethanol and water,
respectively to yield ethanolic and aqueous bark extracts.
Thereafter, the alcoholic extract was evaporated to dry-
ness at 40 ◦C using rotary vacuum evaporator resulting
in a brownish crystalline powder. Similarly, the aqueous
extract was prepared by lyophilization resulting in a
whitish brown free ﬂowing powder. The prepared extracts
were dried and stored in a vacuum dessicator till use.
2.3. Preparation of stock solutions
An accurately weighed amounts of alcoholic and aque-
ous extracts of T. arjuna were solubilized in dimethyl
sulfoxide (DMSO) to result in solutions of ﬁnal concen-
tration 20 mg/mL. Similarly, accurately weighed amounts
of arjunic acid, arjunetin and arjungenin were solubi-
lized individually in methanol to yield solutions of 10 mM
ﬁnal concentrations each. For in vitro assays, stock solu-
tions of probe substrates, testosterone, dextromethorphan
and diclofenac were prepared in acetonitrile at ﬁnal con-
centrations of 40 mM,  1.6 mM and 10 mM,  respectively.
Phosphate buffer (100 mM,  pH 7.4) was used to make
NADPH solution (10 mM).
2.4. Instrument
The high pressure thin layer chromatography (HPTLC)
system consisted of the applicator AS 30, 230V, with
Densitometer CD 60, 230V, with Windows® software
ProQuant®. Analysis of in vitro microsomal assays was
performed using LC-2010HT High Pressure Liquid Chro-
matography system (Shimadzu Corporation, Japan). The
HPLC was equipped with a CBM-20A communication mod-
ule, a SPD-M20A diode array detector, RF-20A ﬂuorescence
detector and LC Solutions® software.
2.5. Estimation of content of arjunic acid, arjunetin and
arjungenin in alcoholic and aqueous extracts of T. arjuna
by HPTLC
The percent w/w content of arjunic acid, arjunetin and
arjungenin in alcoholic and aqueous extracts of T. arjuna
were quantiﬁed using a reported HPTLC method [3]. HPTLC
was performed on 10 cm × 100 cm coated with 0.2 mm
layer of silica gel 60 F254 aluminium backed plates coated.
Stock solutions of arjunic acid, arjunetin and arjungenin
were spotted on the TLC plate to yield spots of con-
centrations in the range of 100–1000 ng/spot each using
the HPTLC DESAGA applicator. The analysis (n = 3) was
performed by comparing and interpolating the extract
peak area (response) with that of the standard arjunic
acid, arjunetin and arjungenin from the calibration curve.
Reported mobile phase (toluene:ethyl acetate:acetic acid
in the ratio of 7:3:0.5) was used to develop the plates [3].
The developed plates were derivatized using anisaldehydeports 2 (2015) 806–816
in sulphuric acid solution. Post derivatization the plates
were dried and scanned with an HPTLC Densitometer CD
60, 230V, with ProQuant Software at 365 nm.
Similarly, accurately 50 mg  of alcoholic and aqueous
extracts were solubilized in 1 mL  methanol and 1 mL dis-
tilled water, respectively. Each of these resulting solutions
were ﬁltered through 0.45  syringe ﬁlter and 20 L of the
solutions (n = 3) were analyzed as mentioned earlier.
2.6. In vitro cytochrome P450 assays
The probe substrates were incubated at their reported
Km values in HLM [9]. Triplicate samples were run to
generate the IC50 values by incubating probe substrates
at a concentration approaching Km in the presence of
different concentrations of test compound in HLM. Alco-
holic and aqueous extracts were evaluated in the range
of 1–100 g/mL ﬁnal concentration, arjunic acid, arjunetin
and arjungenin were evaluated in the range of 1–50 M
ﬁnal concentrations. Triplicate negative and positive con-
trol incubations were run simultaneously. In all the
incubations organic content was  not more than 1% (v/v).
2.6.1. CYP3A4 testosterone 6ˇ-hydroxylase assay in
human liver microsomes
CYP3A4 enzyme activity in human liver microsomes
was  measured on the basis of the probe reaction, 6-
hydroxylation of testosterone by CYP3A4 [9]. Brieﬂy, a
standard 100 L incubation mixture contained liver micro-
somes (0.25 mg/mL  protein concentration), testosterone
in 0.1 M sodium phosphate buffer pH 7.4 at 37 ◦C was
incubated for 30 min  (n = 3) at 100 M [9]. The reactions
were initiated using NADPH (ﬁnal concentration 1 mM)
and then terminated with 50 L of internal standard caf-
feine (50 g/mL) in acetonitrile at the end of 30 min. The
samples were centrifuged at 4000 rpm for 10 min  at 4 ◦C
and the supernatant were subjected to RP-HPLC analysis. A
modiﬁed RP-HPLC method was  used for simultaneous esti-
mation of 6-hydroxy testosterone and testosterone at a
wavelength of 245 nm [2]. Samples were run on a Kromasil
C18 column 5 (4.6 mm  × 150 mm)  and mobile phase used
was  (A) 1 mM Potassium dihydrogen phosphate (KH2PO4)
buffer, pH 3.0 and (B) HPLC grade acetonitrile at a ﬂow rate
of 1 ml/min. The gradient programme used was time: %B
– 0/20; 12/45; 14/55; 16/20; 22/20. The retention times
of caffeine (IS), 6-hydroxy testosterone and testosterone
was  2.8, 8.5 and 16.1 min, respectively. Ketoconazole incu-
bated at a concentration of 0.1 M was run parallel in
triplicate as a positive control [9].
2.6.2. CYP2D6 dextromethorphan O-demethylation assay
in human liver microsomes
CYP2D6 enzyme activity in human liver microsomes
was  measured on the basis of the probe reaction,
O-demethylation of dextromethorphan by CYP2D6 [9].
Brieﬂy, a standard 100 L incubation mixture contained
liver microsomes (0.25 mg/mL protein concentration),
Dextromethorphan in 0.1 M sodium phosphate buffer pH
7.4 at 37 ◦C was  incubated for 30 min  (n = 3) at 8 M [9]. The
reactions were initiated using NADPH (ﬁnal concentration
1 mM)  and then terminated with 50 L of internal standard
A. Varghese et al. / Toxicology Reports 2 (2015) 806–816 809
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erotonin (1 g/mL) in methanol at the end of 30 min. The
amples were centrifuged at 4000 rpm for 10 min  at 4 ◦C
nd the supernatant were subjected to RP-HPLC analysis.
 modiﬁed RP-HPLC method was used for simultaneous
stimation of dextromethorphan, dextrorphan and sero-
onin by ﬂuorescence detection [1]. Samples were run on
 Kromasil C18 column 5 (4.6 mm × 150 mm)  and mobile
hase used was (A) 1 mM Potassium dihydrogen phosphate
KH2PO4) buffer, pH 3.0 and (B) HPLC grade acetonitrile
nd was pumped at a ﬂow rate of 1 mL/min. The gradient
rogramme used was time: %B – 0/10, 8/55, 12/55, 15/10,
7/10. Emission and excitation wavelengths of dextror-
han, dextromethorphan and serotonin used were 320 nm
nd 280 nm,  respectively. The retention times of serotonin
IS), dextrorphan and dextromethorphan was 4.1, 7.6 and
.6 min, respectively. Quinidine was incubated at a concen-
ration of 0.4 M was run parallel in triplicate as a positive
ontrol [9].
.6.3. CYP2C9 diclofenac 4′-hydroxylation assay in
uman liver microsomes
CYP2C9 enzyme activity in human liver microsomes
as measured on the basis of the probe reaction,
′-hydroxylation of diclofenac by CYP2C9 [9]. Brieﬂy,
 standard 100 L incubation mixture contained liver
icrosomes (0.5 mg/mL  protein concentration), diclofenac
odium in 0.1 M sodium phosphate buffer pH 7.4 at 37 ◦C
as incubated for 1 h (n = 3) at 50 M [9]. The reactions
ere initiated with NADPH (ﬁnal concentration 1 mM)  andf T. arjuna in HLM. (a) Inhibition of CYP3A4 enzyme activity. (b) Inhibition
 and aqueous extracts of T. arjuna.
then terminated with 50 L of internal standard serotonin
(1 g/mL) in methanol at the end of an hour. The sam-
ples were centrifuged at 4000 rpm for 10 min  at 4 ◦C and
the supernatant were subjected to RP-HPLC analysis. A
modiﬁed RP-HPLC method was used for simultaneous esti-
mation of diclofenac, 4′-hydroxy diclofenac and phenacetin
by UV detection at 280 nm.  [23]. Samples were run on a
Kromasil C18 column 5 (4.6 mm × 150 mm)  and mobile
phase used was (A) 1 mM potassium dihydrogen phosphate
(KH2PO4) buffer, pH 3.0 and (B) HPLC grade acetonitrile
and was pumped at a ﬂow rate of 1 ml/min. The gradient
programme used was time: %B – 0/10, 5/40, 12/98, 14/10,
15/10. The retention times of phenacetin (IS), 4′-hydroxy
diclofenac and diclofenac was 7.3, 9.4 and 11.2 min, respec-
tively. Sulphaphenazole incubated at a concentration of
0.3 M was run parallel in triplicate as a positive control
[9].
2.7. Data analysis for CYP activities in human liver
microsomes
Percentage inhibition of extracts and T. arjuna standards
to inhibit CYP3A4, CYP2D6 and CYP2C9 enzyme activity
was calculated by the formula mentioned below:
% Inhibition = (AR control − AR sample) × 100
AR control
AR control, area ratio of metabolite/internal standard
in negative control (solvent); AR sample, area ratio of
metabolite/internal standard in presence of extract/
810 A. Varghese et al. / Toxicology Reports 2 (2015) 806–816
Table 1
IC50 values of alcoholic and aqueous extracts of T. arjuna,  arjunic acid, arjunetin and arjungenin for CYP3A4, CYP2D6 and CYP2C9 enzymes in HLM.
Enzyme IC50 values
Alcoholic extract of T. arjuna
(g of extract/mL)
Aqueous extract of T. arjuna
(g of extract/mL)
Arjunic acid Arjunetin Arjungenin
CYP3A4 16.6 ± 6.5 17.4 ± 2.7 >50 M (>25 g/ml) >50 M (>33 g/ml) >50 M (>25 g/ml)
licate.CYP2D6 15.28 ± 4.16 11.97 ± 14.6 
CYP2C9 34.52 ± 3.2 27.78 ± 2.4 
IC50 values, 50% inhibitory concentration. Data represent the mean of trip
standard; IC50 values were calculated using Graph Pad
Prism®.
2.8. Assessment of type of inhibition, inhibition constant
and time-dependent inhibition studies
The inhibition constant (Ki) values of the arjuna extracts
were determined only if their IC50 values were found to be
lower than 100 g/mL.Typically, Ki experiments include a matrix of substrate
and inhibitor concentrations spanning a range of at least
∼0.5–5× expected Ki (inhibitor) and Km (substrate) concen-
trations, respectively. Resulting data is usually represented
Fig. 3. Representative Lineweaver–Burk plot (a) and Dixon plot (b) of effect of alco
liver  microsomes. Representative Lineweaver–Burk plot (c) and Dixon plot (d) of e
in  human liver microsomes.>50 M (>25 g/ml) >50 M (>33 g/ml) >50 M (>25 g/ml)
>50 M (>25 g/ml) >50 M (>33 g/ml) >50 M (>25 g/ml)
in the form of Dixon plots of 1/reaction rate versus inhibitor
concentration [7].
In this study, Ki values and mechanism of inhibition
of alcoholic and aqueous extracts of T. arjuna in HLM for
CYP3A4, CYP2D6 and CYP2C9 were determined by using
testosterone, dextromethorphan and diclofenac at concen-
trations bracketing their reported Km values.
Brieﬂy, testosterone concentrations ranged from 20 to
200 M,  dextromethorphan concentrations ranged from 2
to 16 M and diclofenac concentrations ranged from 20 to
80 M.
Alcoholic and aqueous extracts were incubated in the
range of 2.5–75 g/mL. Ki values were also determined
for selected activities by non-linear regression analysis
holic extract of T. arjuna on 6-hydroxytestosterone formation in human
ffect of aqueous extract of T. arjuna on 6-hydroxytestosterone formation
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f untransformed data to the mixed competitive–non-
ompetitive, uncompetitive, or competitive inhibition
odels using Graph Pad Prism®. Goodness of ﬁt criteria
Akaike’s Information Criterion) was used to determine
he inhibition model that best described the data. The
echanism of inhibition was determined by visual inspec-
ion of the data using Dixon (1/V versus extracts [I])
nd Lineweaver–Burk (1/V versus 1/testosterone [S]) plots
11].
The IC50 shift assay is one of the most efﬁcient and con-
enient methods of evaluating time-dependent inhibitory
ffects of test compounds. When the inhibition curve is
hifted to a lower IC50 value by 30-min pre-incubation
n the presence of NADPH, it is an indication of time-
ependent inhibition [19]. Time dependent inhibition
otential of alcoholic and aqueous extracts of T. arjuna
as determined by preincubating the inhibitor at various
oncentrations, surrounding the IC50 values, with protein
or 30 min  in presence and absence of NADPH. The inac-
ivator was diluted into another incubation tube (ﬁnal
ncubation volume 100 L) containing NADPH generating
ystem and respective substrates (testosterone – 100 M,
extromethorphan – 8 M and diclofenac – 50 M)  and
ADPH (1 mM).  This reaction mixture was incubated for
0 min  at 37 ◦C in a shaking incubator. The reactions
ere terminated, processed and analyzed using HPLC
rocedures as mentioned in Sections 2.6.1–2.6.3. From
he analysis, percentage inhibition of CYP3A4, CYP2D6
nd CYP2C9 enzyme activity by alcoholic and aque-
us extracts of T. arjuna after dilution was computed
n = 3).
. Results
.1. Percent content of arjunic acid, arjunetin and
rjungenin in alcoholic and aqueous extracts of T. arjuna
y HPTLC
Linearity of the calibration curves of arjunic acid,
rjunetin and arjungenin was tested by linear regression
nalysis and found to be linear in the concentration range
00–1000 ng/spot with good correlation between concen-
ration and peak area with a correlation coefﬁcient (r2) of
ore than 0.9980. Average retention factor (Rf) values of
rjunic acid, arjungenin and arjunetin in the given mobile
hase was 0.6, 0.5 and 0.3, respectively, indicating they
ere well resolved. The bands of arjunic acid, arjunetin
nd arjungenin in the extracts were identiﬁed by com-
aring Rf values of reference arjunic acid, arjunetin and
rjungenin. The amount of arjunin acid in alcoholic and
queous extracts was estimated to be about 0.44 ± 0.05%
w/w) and 0.17 ± 0.02% (w/w), respectively. The amount of
rjunetin in alcoholic and aqueous extracts was estimated
o be about 0.33 ± 0.02% (w/w) and 0.07 ± 0.01% (w/w),
espectively. The amount of arjungenin in alcoholic and
queous extracts was estimated to be about 0.23 ± 0.02%
w/w) and 0.16 ± 0.001% (w/w), respectively. The percent
ontent of triterpenoids, arjunic acid, arjunetin and arjun-
enin was found to be more in the alcoholic extract of T.
rjuna. Ta
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Fig. 4. Representative Lineweaver–Burk plot (a) and Dixon plot (b) of effect of alcoholic extract of T. arjuna on dextrorphan formation in human liver
microsomes. Representative Lineweaver–Burk plot (c) and Dixon plot (d) of effect of aqueous extract of T. arjuna on dextrorphan formation in human liver
microsomes.
3.2. Inhibition of CYP3A4, CYP2D6 and CYP2C9 enzyme
in HLM by alcoholic and aqueous extracts of T. arjuna,
arjunic acid, arjunetin and arjungenin
To investigate whether the arjuna extracts and triter-
penoids affect the catalytic activity of CYP3A4, CYP2D6 and
CYP2C9, the probe reaction assay was conducted with var-
ious concentrations of arjuna extracts and triterpenoids in
HLM. Ketoconazole, quinidine and sulphaphenazole at ﬁnal
individual concentrations of 0.1, 0.4 and 0.3 M,  respec-
tively, lead to a 50% inhibition of CYP3A4, CYP2D6 and
CYP2C9 enzyme activity in human liver microsomes as
compared to negative solvent control. Results of the study
summarized in Table 1 and Fig. 2 revealed that both alco-
holic and aqueous extracts of T. arjuna showed potent
CYP3A4, CYP2D6 and CYP2C9 inhibition in HLM with their
IC50 values less than 50 g of extract/mL. However, arjunic
acid, arjunetin and arjungenin showed no signiﬁcant inhi-
bition of CYP3A4, CYP2D6 and CYP2C9 in HLM even upto
50 M concentrations. Among both of the extracts, aque-
ous extract was found to show a relatively more potent
inhibitory effect than alcoholic extract of T. arjuna on
enzyme activities of all the three isozymes in HLM.3.3. Inhibition kinetic analysis
In vitro CYP inhibition assay results suggested that
both alcoholic and aqueous extracts of T. arjuna showed
potent inhibition of CYP3A4, CYP2D6 and CYP2C9 enzymes
in human liver microsomes with IC50 values less than
35 g/mL. However arjunic acid, arjunetin and arjungenin,
did not show any signiﬁcant inhibition of CYP3A4, CYP2D6
and CYP2C9 enzymes in human liver microsomes upto
ﬁnal concentrations of 50 M.  Inhibition constants (Ki
values) and inhibition modes for those with IC50 less
than 100 g/mL (for extracts) or 100 M (for active con-
stituents) need to be determined [25]. Hence mode of
inhibition and Ki values of alcoholic and aqueous extract
of T. arjuna was determined for CYP3A4, CYP2D6 and
CYP2C9 enzymes in human liver microsomes. Since arjunic
acid, arjunetin and arjungenin failed to show any inhi-
bition their Ki values were not determined. Inhibition
constants and mode of inhibition determined for alco-
holic and aqueous extracts of T. arjuna in human liver
microsomes for CYP3A4, CYP2D6 and CYP2C9 enzymes
is summarized in Table 2. Lineweaver–Burk plots and
Dixon plots for alcoholic and aqueous extracts for CYP3A4,
A. Varghese et al. / Toxicology Reports 2 (2015) 806–816 813
Fig. 5. Representative Lineweaver–Burk plot (a) and Dixon plot (b) of effect of alcoholic extract of T. arjuna on 4′-hydroxy diclofenac formation in human
liver  microsomes. Representative Lineweaver–Burk plot (c) and Dixon plot (d) of effect of aqueous extract of T. arjuna on 4′-hydroxy diclofenac formation
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YP2D6 and CYP2C9 inhibition in HLM are shown in
ig. 3(a–d), Fig. 4(a–d) and Fig. 5(a–d), respectively.
For inhibitors of substrates which follow
ichaelis–Menten kinetics tested at the Km concen-
ration of substrate, Ki values fall between IC50/2
competitive inhibitors) and IC50 (non-competitive
nhibitors). Goodness of ﬁt criteria (Akaike’s Information
riterion) was used to determine the best model for
nhibition. Based on Graph Pad Prism® analysis and the
lots it was concluded that the alcoholic and aqueous
xtracts of T. arjuna were non-competitive inhibitors of
YP3A4, CYP2D6 and CYP2C9 enzymes in human liver
icrosomes.
As shown in Fig. 6 on preincubation of alcoholic and
queous extracts for 30 min  in presence and absence of
APDH and diluting the inactivator, there was no shift in
C50 values indicating the interaction to be of a reversible
ype. Based on these evidence it could be postulated that
oth the extracts of T. arjuna are rapidly reversible non-
ompetitive inhibitors.4. Discussion
The stem bark of T. arjuna (Roxb.) is used by the
Ayurvedic physicians in India for the treatment of var-
ious cardiovascular diseases, collectively referred to as
hritroga [12]. Many important biologically active chemi-
cal compounds have been isolated from T. arjuna.  These
include triterpenoids (arjunolic acid, arjunic acid, arjun-
genin, etc.), tannins (ellagic acid, gallic acid), ﬂavonoids
(leucocyanidin, luteolin) and minerals (magnesium, cal-
cium, zinc, etc.) [13]. Various extracts (water, hydroalcohol,
ethanol, etc.) of the stem bark of T. arjuna and active
compounds present in these extracts have been inves-
tigated in many experimental studies and have been
reported to exhibit blood pressure-lowering effects [21],
direct cardioprotective effects [6], antioxidant activities
[16], antiplatelet effects [18], hypolipidemic [10], and anti-
atherogenic effects [17]. Clinical studies have suggested
that arjuna bark extracts at a human dose of 500 mg  three
times daily showed a therapeutic effect comparable to the
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Fig. 6. Effect of 30 min  preincubation (with and without NADPH regenerating system) of extent of inhibition of CYP3A4 mediated testosterone 6′-
ibition 
clofenac
bation hydroxylation by alcoholic (a) and aqueous extract (b) of T. arjuna; inh
(c)  and aqueous (d) extract of T. arjuna;  inhibition of CYP2C9 mediated di
– preincubation for 30 min  with NADPH regenerating system,  – preincu
beneﬁts of isosorbide dinitrate therapy in chronic stable
angina [13].
Although useful, there have been reports cited in the
literature stating the potent effects of herbal drugs on
metabolizing CYP enzymes. It is well documented that any
alteration in the activity of one or several CYP enzymes
could have pronounced effect in the plasma and tis-
sue levels of a co-administered drug. This irregularity in
drug levels could contribute to adverse side effects or
potential toxicity. It could also alter metabolic pathways
of other drugs, which may  lead to inhibition, induc-
tion or activation of other drug metabolizing enzymes
[22].
HPTLC quantiﬁcation showed that the percent content
levels of arjunic acid, arjunetin and arjungenin in alcoholic
extract was approximately 5–15 times more than the
contents in aqueous extract of T. arjuna.  Arjunic acid is
freely soluble in methanol and insoluble in water whereas
arjungenin is freely soluble in methanol and insoluble
in hexane. Arjunic acid and arjungenin are triterpenoid
saponins, which make them non-polar in nature, thusof CYP2D6 mediated dextromethorphan O-demethylation by alcoholic
 4′-hydroxylation by alcoholic (e) and aqueous (f) extract of T. arjuna (
for 30 min  without NADPH regenerating system, – no preincubation).
explaining the difference in its levels in alcoholic and
aqueous bark extracts.
Our previous study reported that alcoholic, hydroalco-
holic and aqueous extracts of T. arjuna showed a potent
inhibition of CYP1A enzyme in rat and human liver micro-
somes with IC50 values less than 50 g/ml. While, arjunic
acid and arjungenin did not show inhibition of CYP1A
enzyme in rat and human liver microsomes [24].
Since CYP3A4, CYP2D6 and CYP2C9 are the three prin-
ciple enzymes to be most commonly responsible for the
metabolism of most drugs and the associated drug–drug
interactions in humans [20]. Hence we investigated the
in vitro inhibitory effect of alcoholic and aqueous extract
of T. arjuna and triterpenoids, arjunic acid, arjunetin and
arjungenin, on CYP3A4, CYP2D6 and CYP2C9 activity in
human liver microsomes.
Of the three isoforms studied, based on the inhibition
constant (Ki values) values, alcoholic and aqueous extracts
of T. arjuna showed a more potent inhibition of CYP2D6
enzyme as compared to CYP3A4 and CYP2C9. Aqueous
extract of T. arjuna showed more potent inhibition of
ology Re
C
h
e
a
a
a
t
i
s
B
i
e
P
a
o
c
e
o
c
e
e
a
e
c
p
s
ﬂ
e
c
a
b
p
s
i
t
a
i
p
a
e
C
m
i
p
C
m
e
a
i
(
t
t
t
s
p
d
a
iA. Varghese et al. / Toxic
YP2D6 enzyme than alcoholic extract of T. arjuna in
uman liver microsomes. The alcoholic and aqueous bark
xtracts of T. arjuna inhibited both CYP3A4 and CYP2C9 to
 similar extent.
Ki values and the Lineweaver–Burk plots, Dixon plots
nd analysis of data using Graph Pad Prism software for
lcoholic and aqueous extracts of T. arjuna,  revealed that
he extracts can be classiﬁed as potent non-competitive
nhibitors. Non-competitive inhibition is rarely seen in
ingle-substrate reactions (multireactant systems) [14].
ased on our results, it is evident that there is signiﬁcant
nhibition of CYP enzymes by arjuna bark extracts, how-
ver there was no inhibition by individual triterpenoids.
reincubation of alcoholic and aqueous bark extract of T.
rjuna in human liver microsomes in presence and absence
f NADPH, followed by dilution of the inactivator did not
ause signiﬁcant reduction of CYP3A4, CYP2D6 and CYP2C9
nzyme activity. Thus, alcoholic and aqueous bark extract
f T. arjuna could be classiﬁed as rapidly reversible non-
ompetitive inhibitors of CYP3A4, CYP2D6 and CYP2C9
nzymes in rats.
As reiterated earlier, despite the difference in the lev-
ls of concentrations of triterpenoids in the alcoholic and
queous extracts the IC50 values and Ki values of both the
xtracts for all the three enzymes were very close further
onﬁrming the absence of inhibitory activity by the triter-
enoids correlating with our in vitro data. The literature
uggests that stem bark of T. arjuna also shows presence of
avonoids like arjunone, luteolin, quercetin, kaempferol,
tc. and tannins like gallic acid, ellagic acid, pyrocate-
hols, terchebulin, etc.  [4]. It is reported that ﬂavonoids
nd tannins are potent CYP inhibitors [26,27]. Since arjuna
ark shows presence of ﬂavonoids and tannins, inhibition
otential of the extracts may  be due to these same con-
tituents which needs to be investigated further. Though it
s important to determine the constituents responsible for
he interaction, it is also essential to note that the extracts
re commonly prescribed as therapeutic agents than the
ndividual constituents. Hence by studying the inhibition
otential of therapeutic extracts with CYP3A4, CYP2D6
nd CYP2C9 enzymes, safety potential of these therapeutic
xtracts could be indexed.
Based on these observations, in vitro inhibition of
YP3A4, CYP2D6 and CYP2C9 enzymes in human liver
icrosomes by extracts of T. arjuna,  suggests that there
s a possibility of T. arjuna to lead to clinically signiﬁcant
harmacokinetic interactions, since CYP3A4, CYP2D6 and
YP2C9 are the main enzymes involved in metabolism of
ost of our drugs. However, effect of T. arjuna bark and
xtracts co-administered with other medications, clinically
nd preclinically need to be investigated. The potential for
n vivo inhibition lies not only with the inhibitory potency
Ki) but also with the overall dispositional properties of
he inhibitor (i.e., extent of absorption from the gastroin-
estinal tract, extent of plasma protein binding, uptake into
he liver, rate of clearance, etc.) [15]. Also, due to lack of
tandardized extracts the relative abundance of each com-
ound in the extracts would also have an impact on the
rug–herb interactions. This, in vitro data can be used as
 guide to design preclinical and clinical pharmacokinetic
nteractions with T. arjuna.ports 2 (2015) 806–816 815
5. Conclusion
Based on our knowledge, inhibition potential of arjuna
bark and its principle phytoconstituents of CYP3A4,
CYP2D6 and CYP2C9 has not been reported. In this study,
we demonstrated that alcoholic and aqueous extracts of
T. arjuna,  a plant used for cardiovascular disorders, have
been identiﬁed to possess strong inhibitory potential of
CYP3A4, CYP2D6 and CYP2C9 enzymes in human liver
microsomes, which is involved in metabolism of many
drugs. The triterpenoids, arjunic acid, arjunetin and arjun-
genin, did not show signiﬁcant inhibition of CYP3A4,
CYP2D6 and CYP2C9 enzymes in human liver microsomes.
Enzyme kinetics and time dependent inhibition studies
classiﬁed alcoholic and aqueous bark extracts as rapidly
reversible non-competitive inhibitors. Until clinical phar-
macokinetic drug interaction experiments are conducted,
the co-administration of drugs, especially those primarily
cleared by CYP3A4, CYP2D6 and CYP2C9 enzymes, with Ter-
minalia arjuna bark extracts should be done with caution.
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